Please login to the form below

Not currently logged in
Email:
Password:

Grifols

This page shows the latest Grifols news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

The setback is also a blow to Spanish drugmaker Grifols, which bought into the phase III programme for Linhaliq in 2013 ago and funded the late-stage trials.

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    2, 180. Hologic (US). Grifols (Spain). Asset acquisition. Nucleic Acid Testing (NAT) technology for R&D and manufacturing of assays and instruments for blood screening. ... The Gold award is won by Grifols, with a 13.6% rise in share price since the

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    1, 800. Novartis / Grifols. Acquisition. Novartis divestment of its blood transfusion testing unit.

  • Pharma deals during November 2013 Pharma deals during November 2013

    In the same vein, Novartis is reviewing its strategy and announced the divestment of its blood transfusion diagnostics unit for $1.7bn to Grifols as part of its ongoing business review.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics